Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips (NYSE: PHG) proposed re-appointment of Roy Jakobs as President & CEO and Board of Management member, to be voted at the AGM on May 8, 2026. The Supervisory Board cited progress since 2022, EUR 2.5 billion productivity savings, restored growth, improved margins, positive cash generation and a stronger balance sheet.
Jakobs will present Philips’ plan to drive profitable growth at the company’s Capital Markets Day later today.
Philips (NYSE:PHG) received Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Digital Pathology–Healthcare Informatics on Jan 29, 2026.
The award cites Philips' integrated digital pathology portfolio, FDA 510(k) clearance for primary diagnosis, >3,500 pathologists across 40+ countries, and >38 million slides scanned globally.
Royal Philips (NYSE: PHG) was named a Clarivate Top 100 Global Innovator for 2026 on January 21, 2026, its 13th consecutive year on the list and the highest-ranking medical technology company included.
Recognition highlights Philips' long-term innovation focus, supported by more than EUR 1.7 billion in annual R&D investment (about 9% of sales). Recent innovations cited include the Philips Verida detector-based spectral CT, helium-free MRI magnet technology with >2,000 installations and ~6 million liters of helium saved, the Flash 5100 point-of-care ultrasound, a next-generation web diagnostic viewer, and AI-enabled consumer care products.
Heartstream (formerly Philips Emergency Care) launched as an independent emergency care company on Jan 14, 2026 after Emergency Care Holdings (ECH), a Bridgefield Capital platform, completed its acquisition of the Philips Emergency Care business from Royal Philips (NYSE: PHG). Heartstream will operate under a multi-year Philips brand licensing agreement and will continue to manufacture AEDs, professional defibrillators, Tempus and Intrepid monitoring systems, and integrated software.
The company cites >100 years of cardiac monitoring heritage and >40 years in defibrillator solutions and plans to expand AED access, strengthen supply chain resilience, modernize digital solutions, and broaden its global footprint.
Emergency Care Holdings (NYSE:PHG) completed its acquisition of the Philips Emergency Care business on January 14, 2026, launching a global emergency care platform operating as Heartstream under a Philips brand license.
The business serves the pre-hospital market across more than 130 countries, supported by about 480 distribution partners, an installed base exceeding 3 million AEDs and ALS devices, and roughly 600 employees. ECH, backed by Bridgefield Capital, positions the unit for scaled, profitable growth via disciplined, complementary acquisitions across diagnostics, therapies, services, equipment and informatics in a global $26B emergency medical products market.
Royal Philips (NYSE: PHG) announced on December 15, 2025 an agreement to acquire SpectraWAVE, adding the HyperVue Imaging System (DeepOCT + NIRS) and X1-FFR (angiography-derived, AI-enabled FFR) to Philips’ coronary intravascular imaging and physiology portfolio.
The deal will integrate SpectraWAVE technologies with Philips’ Azurion platform and existing Eagle Eye Platinum IVUS and OmniWire iFR devices, expanding clinician options for intravascular imaging and physiology. Financial terms were not disclosed. SpectraWAVE is based in Bedford, Massachusetts, employs ~70 people, and its HyperVue and X1-FFR products hold US FDA Class 2 clearances.
Royal Philips (NYSE: PHG) reaffirmed on 4 December 2025 that its 2026 outlook will be published on 10 February 2026 as previously scheduled. The company said it expects continued performance improvement with sequential comparable sales growth, expanded margins despite tariff headwinds, and strong cash flow.
Philips reiterated an expectation that comparative sales growth will accelerate sequentially in 2026 toward mid-single-digit growth, supported by solid order momentum and consistent with the last four quarters. The company has not released an early view of formal guidance and will share its full outlook on 10 February 2026.
Philips (NYSE: PHG) announced expanded commercial availability of LumiGuide, the first real-time AI-enabled, light-based 3D navigation solution for image-guided therapy, across Europe and the United States, with commercial orders starting January 2026. LumiGuide uses Fiber Optic RealShape (FORS) to visualize guidewires and compatible catheters in 3D without continuous X-ray and integrates with the Azurion image-guided therapy platform. Philips cites clinical use in >2,000 procedures and a referenced single-center study reporting procedures up to 37% faster and up to 56% DAP reduction. LumiGuide has FDA clearance and CE marking.
Philips (NYSE: PHG) launched Verida, described as the world’s first detector-based spectral CT fully powered by AI, announced at RSNA 2025 on November 30, 2025. Verida integrates AI across acquisition and reconstruction to deliver higher spectral and conventional image quality, claims dramatic dose reduction, up to 45% energy savings, and reconstructs 145 images/sec enabling exams to appear in <30 seconds and up to 270 exams/day. Verida is CE-marked, 510(k) pending, and availability in select markets begins in 2026.
Royal Philips (NYSE: PHG) on November 30, 2025 unveiled BlueSeal Horizon, an industry-first helium-free 3.0T MRI platform presented at RSNA 2025. The platform pairs a 3.0T helium-free magnet (with 7 liters permanently enclosed) with AI-powered workflow and imaging tools.
Philips cites prior BlueSeal scale: >2,000 1.5T installs and >6 million liters of liquid helium saved (compared with prior-generation magnets). Key AI features announced include SmartSpeed Precise (up to 3x faster scans; up to 80% sharper images), SmartPlanning (automated planning in as little as 30 seconds), real-time scan preview powered by NVIDIA, and SmartReading for cloud-based reading and reporting.
Disclosure: BlueSeal Horizon is a work in progress, not available in any jurisdiction and not for sale in the USA; future availability is not ensured.